Amanote Research
Register
Sign In
High Rate of Morbid Central Line Associated Complications During Treatment With Dose-Adjusted R-Epoch Therapy for Non-Hodgkin Lymphoma
Hematological Oncology
- United Kingdom
doi 10.1002/hon.2439_193
Full Text
Open PDF
Abstract
Available in
full text
Categories
Medicine
Cancer Research
Oncology
Hematology
Date
June 1, 2017
Authors
P. Reagan
R. David
A. Baran
J. Kelly
K. Loh
C. Casulo
P. Barr
J. Friedberg
Publisher
Wiley
Related search
Dose-Adjusted Epoch for Lymphoma-Associated Hemophagocytic Lymphohistiocytosis: A Stone Two Birds
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Bendamustine-Based Therapy as First-Line Treatment for Non-Hodgkin Lymphoma
Medical Oncology
Medicine
Cancer Research
Oncology
Hematology
Frequency, Risk Factors, and Outcomes of Central Nervous System Relapse in Lymphoma Patients Treated With Dose-Adjusted EPOCH Plus Rituximab
American Journal of Hematology
Hematology
Favorable Outcomes in Elderly Patients Undergoing High-Dose Therapy and Autologous Stem Cell Transplantation for Non-Hodgkin Lymphoma
Biology of Blood and Marrow Transplantation
Transplantation
Hematology
Recent Advances in the First-Line Treatment of Follicular Non-Hodgkin Lymphoma
F1000Research
Genetics
Molecular Biology
Pharmacology
Biochemistry
Microbiology
Immunology
Medicine
Toxicology
Pharmaceutics
Modern Radiation Therapy for Nodal Non-Hodgkin Lymphoma—Target Definition and Dose Guidelines From the International Lymphoma Radiation Oncology Group
International Journal of Radiation Oncology Biology Physics
Oncology
Radiology
Cancer Research
Radiation
Nuclear Medicine
Imaging
Treatment of Early Stages Hodgkin Lymphoma During Pregnancy
Mediterranean Journal of Hematology and Infectious Diseases
Infectious Diseases
Hematology
A Phase I Trial of 19-28z Car-T Cells Post-High Dose Therapy and Autologous Transplantation (Hdt-Asct) for Relapsed and Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (B-Nhl)
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Palliative Therapy for Recalcitrant Cutaneous T-Cell Lymphoma of the Hands and Feet With Low-Dose, High Dose-Rate Brachytherapy
JAMA Dermatology
Dermatology
Medicine